Evidence map›Paper›PMID 34056385›Full record

ArticleACS omega2021

pH-Responsive Pluronic F127-Lenvatinib-Encapsulated Halogenated Boron-Dipyrromethene Nanoparticles for Combined Photodynamic Therapy and Chemotherapy of Liver Cancer.

Jingjing Zong, Hao Peng, Xin Qing, Zhe Fan, Wenjing Xu, Xuanlong Du, Ruihua Shi, Yewei Zhang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. RAFT Synthesis and Characterization of Poly(Butyl-Materials (Basel, Switzerland) · 2023
    Article
  10. Article
  11. Near-Infrared Dyes: Towards Broad-Spectrum Antivirals.International journal of molecular sciences · 2022
    Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Jingjing ZongDepartment of General Surgery, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China.
Hao PengDepartment of General Surgery, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China.
Xin QingDepartment of General Surgery, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China.
Zhe FanDepartment of General Surgery, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China.
Wenjing XuDepartment of General Surgery, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China.
Xuanlong DuDepartment of General Surgery, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China.
Ruihua ShiDepartment of Gastroenterology, Zhongda Hospital, School of Medicine, Southeast University, No. 87 Dingjiaqiao, Nanjing 210009, China.
Yewei ZhangDepartment of General Surgery, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, China.ORCID 0000-0002-5589-3630
Zhongda Hospital Southeast University · CNDalian Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Combination therapy such as photodynamic therapy (PDT)-enhanced chemotherapy is regarded as a promising strategy for cancer treatment. Boron-dipyrromethene (BODIPY), as close relatives of porphyrins, was widely used in PDT. However, poor water solubility, rapid metabolism by the body and lack of targeting limits its clinical application. Lenvatinib, as the first-line drug for molecular-targeted therapy of liver cancer, restricted its clinical application for its side effects. Herein, to achieve the synergy between PDT and chemotherapy, we synthesized two halogenated BODIPY, BDPBr

Identifiers

PMID34056385
PMCPMC8154152
OpenAlexW3159748855

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.